From Development to Clinical Success: the Journey of Established and Next-generation BTK Inhibitors

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2025 Feb 27

PMID 40014234

Authors

Shivani Gupta

Arpit Sharma

Alok Shukla

Abha Mishra

Amit Singh

Affiliations

Soon will be listed here.

Abstract

Over the past decade, Bruton's tyrosine kinase (BTK) has emerged as a pivotal therapeutic target for B-cell malignancies and autoimmune diseases, given its essential role in B-cell development and function. Dysregulation of BTK signalling is implicated in a range of hematologic cancers, including Waldenström's macroglobulinaemia (WM), mantle cell lymphoma (MCL), and chronic lymphocytic leukaemia (CLL). The development of BTK inhibitors (BTKIs), starting with ibrutinib, has revolutionized the treatment of these malignancies by inhibiting B-cell receptor (BCR) signalling and inducing apoptosis in malignant B-cells. Despite the impressive clinical efficacy of ibrutinib, challenges such as resistance mutations and off-target effects remain. To address these issues, next-generation BTKIs, including acalabrutinib, orelabrutinib, zanubrutinib, and pirtobrutinib, have been developed, offering improved specificity and reduced toxicity profiles. This review highlights the therapeutic potential of BTK-targeted therapies in treating B-cell malignancies, discusses recent advancements with FDA-approved BTKIs, and explores the latest clinical outcomes from ongoing trials of novel inhibitors.

References

Rawlings D, Witte O . Bruton's tyrosine kinase is a key regulator in B-cell development. Immunol Rev. 1994; 138:105-19. DOI: 10.1111/j.1600-065x.1994.tb00849.x. View

Wu H, Wang W, Liu F, Weisberg E, Tian B, Chen Y . Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014; 9(5):1086-91. PMC: 4027949. DOI: 10.1021/cb4008524. View

Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F . The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993; 361(6409):226-33. DOI: 10.1038/361226a0. View

BRUTON O . Agammaglobulinemia. Pediatrics. 1952; 9(6):722-8. View

Suri D, Rawat A, Singh S . X-linked Agammaglobulinemia. Indian J Pediatr. 2016; 83(4):331-7. DOI: 10.1007/s12098-015-2024-8. View

Valiaho J, Smith C, Vihinen M . BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat. 2006; 27(12):1209-17. DOI: 10.1002/humu.20410. View

Tsukada S, Saffran D, Rawlings D, Parolini O, Allen R, Klisak I . Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993; 72(2):279-90. DOI: 10.1016/0092-8674(93)90667-f. View

Riggs J, Howell K, Matechin B, Matlack R, Pennello A, Chiasson R . X-chromosome-linked immune-deficient mice have B-1b cells. Immunology. 2003; 108(4):440-51. PMC: 1782925. DOI: 10.1046/j.1365-2567.2003.01624.x. View

Liu X, Zhan Z, Li D, Xu L, Ma F, Zhang P . Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol. 2011; 12(5):416-24. DOI: 10.1038/ni.2015. View

10.

Quek L, Bolen J, Watson S . A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998; 8(20):1137-40. DOI: 10.1016/s0960-9822(98)70471-3. View

11.

Honda F, Kano H, Kanegane H, Nonoyama S, Kim E, Lee S . The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol. 2012; 13(4):369-78. DOI: 10.1038/ni.2234. View

12.

Genevier H, Hinshelwood S, Gaspar H, Rigley K, Brown D, Saeland S . Expression of Bruton's tyrosine kinase protein within the B cell lineage. Eur J Immunol. 1994; 24(12):3100-5. DOI: 10.1002/eji.1830241228. View

13.

Katz F, Lovering R, Bradley L, Rigley K, Brown D, Cotter F . Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia. Leukemia. 1994; 8(4):574-7. View

14.

Brullo C, Villa C, Tasso B, Russo E, Spallarossa A . Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. Int J Mol Sci. 2021; 22(14). PMC: 8303217. DOI: 10.3390/ijms22147641. View

15.

Manji F, Puckrin R, Stewart D . Novel synthetic drugs for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother. 2021; 22(11):1417-1427. DOI: 10.1080/14656566.2021.1902988. View

16.

Schmidt U, Boucheron N, Unger B, Ellmeier W . The role of Tec family kinases in myeloid cells. Int Arch Allergy Immunol. 2004; 134(1):65-78. DOI: 10.1159/000078339. View

17.

Hyvonen M, Saraste M . Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. EMBO J. 1997; 16(12):3396-404. PMC: 1169965. DOI: 10.1093/emboj/16.12.3396. View

18.

Varnai P, Rother K, Balla T . Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells. J Biol Chem. 1999; 274(16):10983-9. DOI: 10.1074/jbc.274.16.10983. View

19.

Kang S, Wahl M, Chu J, Kitaura J, Kawakami Y, Kato R . PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J. 2001; 20(20):5692-702. PMC: 125669. DOI: 10.1093/emboj/20.20.5692. View

20.

Vihinen M, Nilsson L, Smith C . Tec homology (TH) adjacent to the PH domain. FEBS Lett. 1994; 350(2-3):263-5. DOI: 10.1016/0014-5793(94)00783-7. View